Long non-coding RNA (lncRNA) H19 in human cancer: From proliferation and metastasis to therapy

Pharmacological Research, Journal Year: 2022, Volume and Issue: 184, P. 106418 - 106418

Published: Aug. 28, 2022

Language: Английский

---

Tantalum–Zirconium Co‐Doped Metal–Organic Frameworks Sequentially Sensitize Radio–Radiodynamic–Immunotherapy for Metastatic Osteosarcoma

Advanced Science, Journal Year: 2023, Volume and Issue: 10(10)

Published: Feb. 5, 2023

Due to radiation resistance and the immunosuppressive microenvironment of metastatic osteosarcoma, novel radiosensitizers that can sensitize radiotherapy (RT) antitumor immunity synchronously urgently needed. Here, authors developed a nanoscale metal-organic framework (MOF, named TZM) by co-doping high-atomic elements Ta Zr as metal nodes porphyrinic molecules (tetrakis(4-carboxyphenyl)porphyrin (TCPP)) photosensitizing ligand. Given 3D arrays ultra-small heavy metals, porous TZM serves an efficient attenuator absorbing X-ray energy sensitizing hydroxyl radical generation for RT. Ta-Zr narrowed highest occupied molecular orbital-lowest unoccupied orbital (HOMO-LUMO) gap exhibited close levels between singlet triplet photoexcited states, facilitating transfer photosensitizer TCPP oxygen (

Language: Английский

---

Metastatic Progression of Osteosarcomas: A Review of Current Knowledge of Environmental versus Oncogenic Drivers

Cancers, Journal Year: 2022, Volume and Issue: 14(2), P. 360 - 360

Published: Jan. 12, 2022

Metastases of osteosarcomas are heterogeneous. They may grow simultaneously with the primary tumor, during treatment or shortly after, a long time after end treatment. occur mainly in lungs but also bone and various soft tissues. can have same histology as tumor show shift towards different differentiation path. However, metastatic capacities osteosarcoma cells be predicted by gene microRNA signatures. Despite identification numerous metastasis-promoting/predicting factors, there is no efficient therapeutic strategy to reduce number patients developing disease cure these patients, except surgery. Indeed, generally resistant classical chemo- immuno-therapy. Hence, knowledge specific mechanisms should extended reveal novel approaches. Recent studies that used DNA RNA sequencing technologies highlighted complex relations between secondary tumors. The reported results supported hierarchical organization cell clones, suggesting cancer stem involved. Because their chemoresistance, plasticity, ability modulate immune environment, could important players process.

Language: Английский

---

Zinc oxide nanoparticles inhibit osteosarcoma metastasis by downregulating β-catenin via HIF-1α/BNIP3/LC3B-mediated mitophagy pathway

Bioactive Materials, Journal Year: 2022, Volume and Issue: 19, P. 690 - 702

Published: May 13, 2022

Osteosarcoma (OS) therapy faces many challenges, especially the poor survival rate once metastasis occurs. Therefore, it is crucial to explore new OS treatment strategies that can efficiently inhibit metastasis. Bioactive nanoparticles such as zinc oxide (ZnO NPs) growth, however, effect and mechanisms of them on tumor are still not clear. In this study, we firstly prepared well-dispersed ZnO NPs proved metastasis-related malignant behaviors including migration, invasion, epithelial-mesenchymal transition (EMT). RNA-Seqs found differentially expressed genes (DEGs) in NP-treated cells were enriched wingless/integrated (Wnt) hypoxia-inducible factor-1 (HIF-1) signaling pathway. We further Zn2+ released from induced downregulation β-catenin expression via HIF-1α/BNIP3/LC3B-mediated mitophagy combined with ICG-001, a inhibitor, showed synergistic inhibitory lung longer time. addition, tissue microarray (TMA) patients also detected much higher which indicated role development. summary, our current study only by degrading pathway, but provided far-reaching potential clinical

Language: Английский

---

Extracellular vesicles: A new diagnostic biomarker and targeted drug in osteosarcoma

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Sept. 23, 2022

Osteosarcoma (OS) is a primary bone cancer that highly prevalent among adolescents and adults below the age of 20 years. The prognostic outcome metastatic OS or relapse extremely poor; thus, developing new diagnostic therapeutic strategies for treating necessary. Extracellular vesicles (EVs) ranging from 30–150 nm in diameter are commonly produced different cells found various types body fluids. EVs rich biologically active components like proteins, lipids, nucleic acids. They also strongly affect pathophysiological processes by modulating intercellular signaling pathways exchange biomolecules. Many studies have influence occurrence, development, metastasis osteosarcoma. regulation inflammatory communication affects other bone-related pathological conditions, such as osteoarthritis rheumatoid arthritis. In this study, we reviewed latest findings related to diagnosis, prognosis prediction, development treatment perspective EVs.

Language: Английский

---

Novel roles of PIWI proteins and PIWI-interacting RNAs in human health and diseases

Cell Communication and Signaling, Journal Year: 2023, Volume and Issue: 21(1)

Published: Nov. 29, 2023

Abstract Non-coding RNA has aroused great research interest recently, they play a wide range of biological functions, such as regulating cell cycle, proliferation, and intracellular substance metabolism. Piwi-interacting RNAs (piRNAs) are emerging small non-coding that 24–31 nucleotides in length. Previous studies on piRNAs were mainly limited to evaluating the binding PIWI protein family role. However, recent have shed more lights piRNA functions; aberrant unique roles many human diseases, including diverse lethal cancers. Therefore, understanding mechanism expression specific functional diseases is crucial for developing its clinical applications. Presently, focuses their cancer-specific functions but lacks investigation expressions epigenetic modifications. This review discusses piRNA’s biogenesis progress piRNA/PIWI complexes diseases.

Language: Английский

---

Unveiling the Protective Role of Melatonin in Osteosarcoma: Current Knowledge and Limitations

Biomolecules, Journal Year: 2024, Volume and Issue: 14(2), P. 145 - 145

Published: Jan. 24, 2024

Melatonin, an endogenous neurohormone produced by the pineal gland, has received increased interest due to its potential anti-cancer properties. Apart from well-known role in sleep–wake cycle, extensive scientific evidence shown various physiological and pathological processes, such as inflammation. Additionally, melatonin demonstrated promising agent function includes inhibition of tumorigenesis, induction apoptosis, regulation anti-tumor immune response. Although a precise pathophysiological mechanism is yet be established, several pathways related cell cycle progression, DNA repair mechanisms, antioxidant activity have been implicated anti-neoplastic melatonin. In current manuscript, we focus on properties use treating managing pediatric osteosarcoma. This aggressive bone tumor primarily affects children adolescents treated mainly surgical radio-oncological interventions, which improved survival rates among affected individuals. Significant disadvantages these interventions include disease recurrence, therapy-related toxicity, severe/debilitating side effects that patients endure, significantly affecting their quality life. Melatonin therapeutic when used for osteosarcoma, attributed ability halt cancer proliferation trigger apoptotic death, thereby enhancing chemotherapeutic efficacy. Furthermore, antioxidative alleviates harmful chemotherapy-induced oxidative damage, aiding decreasing toxicities. The review concisely explains many mechanisms targets evidenced significant results vitro animal models. Nevertheless, if further explored, human trials remain challenge could shed light support utility adjunctive modality

Language: Английский

---

Programmable readout sensor for microRNA: CRISPR/Cas12a-assisted multi-amplification strategy activated photoelectrochemistry-colorimetry detection

Sensors and Actuators B Chemical, Journal Year: 2022, Volume and Issue: 371, P. 132585 - 132585

Published: Sept. 1, 2022

Language: Английский

---

A novel 3-miRNA network regulates tumour progression in oral squamous cell carcinoma

Biomarker Research, Journal Year: 2023, Volume and Issue: 11(1)

Published: June 14, 2023

Abstract Background Late diagnosis is one of the major confounders in oral squamous cell carcinoma (OSCC). Despite recent advances molecular diagnostics, no disease-specific biomarkers are clinically available for early risk prediction OSCC. Therefore, it important to identify robust that detectable using non-invasive liquid biopsy techniques facilitate cancer. This study identified potential salivary exosome-derived miRNA and crucial miRNA-mRNA networks/underlying mechanisms responsible OSCC progression. Methods Small RNASeq (n = 23) was performed order both tissue exosomes derived from patients. Further, integrated analysis The Cancer Genome Atlas (TCGA) datasets 114), qPCR validation on larger patient cohorts 70) statistical with various clinicopathological parameters conducted assess effectiveness signature. networks pathway by integrating transcriptome sequencing TCGA data. OECM-1 line transfected signature observe its effect functional such as proliferation, cycle, apoptosis, invasive well migratory downstream signaling pathways regulated these networks. Results data 12 differentially expressed miRNAs patients compared controls. On validating findings a cohort patients, miR-140-5p, miR-143-5p, miR-145-5p were found be significantly downregulated. 3-miRNA demonstrated higher efficacy predicting disease progression correlated poor prognosis (p < 0.05). Transcriptome, TCGA, network HIF1a, CDH1, CD44, EGFR, CCND1 hub genes transfection-mediated upregulation decreased induced resulted G2/M phase cycle arrest reduced reversing EMT process line. Conclusions Thus, this identifies can utilized biomarker uncovers underlying converting normal epithelial into malignant phenotype.

Language: Английский

---

Biodegradable FePS3 nanoplatform for efficient treatment of osteosarcoma by combination of gene and NIR-II photothermal therapy

Journal of Nanobiotechnology, Journal Year: 2023, Volume and Issue: 21(1)

Published: July 13, 2023

As a common tumor with high incidence, osteosarcoma possesses extremely poor prognosis and mortality. Improving the survival of patients is still great challenge due to precipice advancement in treatment. In this study, combination strategy gene therapy photothermal (PTT) developed for efficient treatment osteosarcoma. Two-dimensional (2D) FePS3 nanosheets are synthesized functionalized by poly-L-lysine-PEG-folic acid (PPF) fabricate multifunctional nanoplatform (FePS@PPF) further loading microRNAs inhibitor, miR-19a inhibitor (anti-miR-19a). The conversion efficiency FePS@PPF up 47.1% under irradiation 1064 nm laser. vitro study shows that anti-miR-19a can be efficiently internalized into cells through protection delivery nanaocarrier, which induces up-regulation PTEN protein down-regulation p-AKT protein. After intravenous injection, specifically accumulates site osteosarcoma-bearing mice. vivo investigations reveal combined PTT-gene displays most significant ablation compared monotherapy. More importantly, good biodegradability promotes cleared from body avoiding potential toxicity long-term retention. Our work not only develops NIR-II PTT mediated anti-miR-19a/FePS@PPF but also provides insights design applications other nanotherapeutic platforms.

Language: Английский

---